TORNTPHARM Torrent Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Management summary
- Torrent Pharma delivered a strong Q3 FY26 performance characterized by double-digit growth in its core branded markets of India and Brazil.
- The quarter was headlined by the acquisition of a controlling stake in JB Pharma, which is expected to drive significant cost synergies and margin expansion over the next three years.
- While the Germany business faced supply chain disruptions, the US business showed signs of recovery through new launches, and the company remains focused on scaling its chronic therapy presence.
Source: Inve concall analysis and management guidance record.
What they filed
Q3 FY26: revenue up 9.3%, net profit up 19.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,377 | 2,433 | 2,616 | 2,762 | 2,599 +9% |
| EBITDA | 887 | 868 | 979 | 1,072 | 1,000 +13% |
| Net profit | 485 | 474 | 551 | 597 | 577 +19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Margin
JB Pharma Cost Synergies Margin · next 2-3 years · High confidence ₹400-450 crores
Headcount
India Field Force Strength Headcount · FY26 · High confidence 7,000+
From 6,800 today
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2JB Pharma Consolidation and Synergies Direct
consolidation, Damayanti, is line-by-line only. So, effective from 21st January till 31st March, the Quarter 4 numbers will include JB numbers.
Clarifies that the acquisition will immediately impact the P&L on a consolidated basis, allowing investors to model the full impact of JB's financials.
Asked by Damayanti Kerai, HSBC
Germany Supply Disruption Timeline Evasive
I cannot give a timeline because our supplier is caught up in regulatory issues... it will take at least 3 to 4 quarters to get an alternate supplier on board.
Highlights a significant near-term risk in the European business with no immediate resolution, potentially dragging down overall growth for the next year.
Asked by Damayanti Kerai, HSBC
Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 4 risks, concerns & management red flags
- Watchlist triggers for Q4 FY26
- +3 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





